Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.92 USD | -0.91% |
|
-0.48% | -0.80% |
07-10 | XOMA Corporation will Change its Name to XOMA Royalty Corporation | CI |
07-09 | Xoma Changes Name to Xoma Royalty | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past twelve months, EPS forecast has been revised upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.80% | 314M | - | ||
+20.17% | 127B | B+ | ||
+24.67% | 117B | B+ | ||
+25.44% | 27.67B | B | ||
-17.74% | 20.33B | B+ | ||
-15.17% | 16.79B | A- | ||
-15.21% | 15.63B | B | ||
+11.91% | 14.84B | C+ | ||
-47.10% | 14.65B | A- | ||
+54.50% | 14.43B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- XOMA Stock
- XOMAO Stock
- Ratings XOMA Royalty Corporation